MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Corporate

MOUNTAIN VIEW, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress , being held in collaboration with the Danish Society

-- Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G)

MOUNTAIN VIEW, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of avacopan in the treatment

MOUNTAIN VIEW, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in April: H.C. Wainwright Global Life Sciences Conference Monday,

-- Peer-reviewed findings show blocking CCR2 provides rapid and sustained renal benefit in well-established models of FSGS -- -- Improvements in renal function with CCR2 inhibition associated with encouraging histological changes, including increased podocyte density -- MOUNTAIN VIEW, Calif.

-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application -- -- Strengthened balance sheet with up to $100 million in new capital commitments;

MOUNTAIN VIEW, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38 th Annual Health Care Conference on Tuesday March 13, 2018 at 10:40 a.m. ET .